135 related articles for article (PubMed ID: 11697756)
1. Pharmacokinetics of norelgestromin and ethinyl estradiol from two consecutive contraceptive patches.
Abrams LS; Skee DM; Wong FA; Anderson NJ; Leese PT
J Clin Pharmacol; 2001 Nov; 41(11):1232-7. PubMed ID: 11697756
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of a contraceptive patch (Evra/Ortho Evra) containing norelgestromin and ethinyloestradiol at four application sites.
Abrams LS; Skee DM; Natarajan J; Wong FA; Anderson GD
Br J Clin Pharmacol; 2002 Feb; 53(2):141-6. PubMed ID: 11851637
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of norelgestromin and ethinyl estradiol delivered by a contraceptive patch (Ortho Evra/Evra) under conditions of heat, humidity, and exercise.
Abrams LS; Skee DM; Natarajan J; Wong FA; Leese PT; Creasy GW; Shangold MM
J Clin Pharmacol; 2001 Dec; 41(12):1301-9. PubMed ID: 11762557
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic overview of Ortho Evra/Evra.
Abrams LS; Skee D; Natarajan J; Wong FA
Fertil Steril; 2002 Feb; 77(2 Suppl 2):S3-12. PubMed ID: 11849630
[TBL] [Abstract][Full Text] [Related]
5. Transdermal contraception.
Creasy GW; Abrams LS; Fisher AC
Semin Reprod Med; 2001 Dec; 19(4):373-80. PubMed ID: 11727179
[TBL] [Abstract][Full Text] [Related]
6. Multiple-dose pharmacokinetics of a contraceptive patch in healthy women participants.
Abrams LS; Skee DM; Natarajan J; Wong FA; Lasseter KC
Contraception; 2001 Nov; 64(5):287-94. PubMed ID: 11777488
[TBL] [Abstract][Full Text] [Related]
7. The pharmacokinetics of 12-week continuous contraceptive patch use.
Lavelanet AF; Rybin D; White KO
Contraception; 2017 Jun; 95(6):578-585. PubMed ID: 28285154
[TBL] [Abstract][Full Text] [Related]
8. The Evra (ethinyl estradiol/norelgestromin) contraceptive patch: estrogen exposure concerns.
Wooltorton E
CMAJ; 2006 Jan; 174(2):164-5. PubMed ID: 16368722
[No Abstract] [Full Text] [Related]
9. Ortho Evra/Evra versus oral contraceptives: follicular development and ovulation in normal cycles and after an intentional dosing error.
Pierson RA; Archer DF; Moreau M; Shangold GA; Fisher AC; Creasy GW
Fertil Steril; 2003 Jul; 80(1):34-42. PubMed ID: 12849799
[TBL] [Abstract][Full Text] [Related]
10. A comparative and pooled analysis of the safety and tolerability of the contraceptive patch (Ortho Evra/Evra).
Sibai BM; Odlind V; Meador ML; Shangold GA; Fisher AC; Creasy GW
Fertil Steril; 2002 Feb; 77(2 Suppl 2):S19-26. PubMed ID: 11849632
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetics and pharmacodynamics of a transdermal contraceptive patch and an oral contraceptive.
Devineni D; Skee D; Vaccaro N; Massarella J; Janssens L; LaGuardia KD; Leung AT
J Clin Pharmacol; 2007 Apr; 47(4):497-509. PubMed ID: 17389559
[TBL] [Abstract][Full Text] [Related]
12. Integrated summary of Ortho Evra/Evra contraceptive patch adhesion in varied climates and conditions.
Zacur HA; Hedon B; Mansour D; Shangold GA; Fisher AC; Creasy GW
Fertil Steril; 2002 Feb; 77(2 Suppl 2):S32-5. PubMed ID: 11849634
[TBL] [Abstract][Full Text] [Related]
13. Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188.
Vogler MA; Patterson K; Kamemoto L; Park JG; Watts H; Aweeka F; Klingman KL; Cohn SE
J Acquir Immune Defic Syndr; 2010 Dec; 55(4):473-82. PubMed ID: 20842042
[TBL] [Abstract][Full Text] [Related]
14. Transdermal ethinylestradiol/norelgestromin: a review of its use in hormonal contraception.
Goa KL; Warner GT; Easthope SE
Treat Endocrinol; 2003; 2(3):191-206. PubMed ID: 15966567
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic overview of ethinyl estradiol dose and bioavailability using two transdermal contraceptive systems and a standard combined oral contraceptive.
Hofmann B; Reinecke I; Schuett B; Merz M; Zurth C
Int J Clin Pharmacol Ther; 2014 Dec; 52(12):1059-70. PubMed ID: 25295716
[TBL] [Abstract][Full Text] [Related]
16. The effect of efavirenz on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy HIV-negative women.
Sevinsky H; Eley T; Persson A; Garner D; Yones C; Nettles R; Krantz K; Bertz R; Zhang J
Antivir Ther; 2011; 16(2):149-56. PubMed ID: 21447863
[TBL] [Abstract][Full Text] [Related]
17. Assessment of compliance with a weekly contraceptive patch (Ortho Evra/Evra) among North American women.
Archer DF; Bigrigg A; Smallwood GH; Shangold GA; Creasy GW; Fisher AC
Fertil Steril; 2002 Feb; 77(2 Suppl 2):S27-31. PubMed ID: 11849633
[TBL] [Abstract][Full Text] [Related]
18. Extended use of transdermal norelgestromin/ethinyl estradiol: a randomized trial.
Stewart FH; Kaunitz AM; Laguardia KD; Karvois DL; Fisher AC; Friedman AJ
Obstet Gynecol; 2005 Jun; 105(6):1389-96. PubMed ID: 15932834
[TBL] [Abstract][Full Text] [Related]
19. Effect of laropiprant, a PGD2 receptor 1 antagonist, on estradiol and norgestimate pharmacokinetics after oral contraceptive administration in women.
Schwartz JI; Liu F; Wang YH; Pramanik B; Johnson-Levonas AO; Gutierrez MJ; Lai E; Wagner JA
Am J Ther; 2009; 16(6):487-95. PubMed ID: 19940609
[TBL] [Abstract][Full Text] [Related]
20. Comparison of a transdermal contraceptive patch with a newly sourced adhesive component versus EVRA patch: A double-blind, randomized, bioequivalence and adhesion study in healthy women.
Parasrampuria DA; Vaughan S; Ariyawansa J; Swinnen A; Natarajan J; Rasschaert F; Massarella J; Fonseca S
Contraception; 2020 Apr; 101(4):276-282. PubMed ID: 31935382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
